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Background: In pre-clinical models enhanced anti-tumour activity was observed when SU-
014813, an oral multi-targeted tyrosine kinase inhibitor was combined with docetaxel. This
synergy might be explained by improvement of the penetration of cytotoxic agents into
tumours as a result of both VEGFR and PDGFR inhibition. We assessed the maximal toler-
ated dose (MTD), evaluated the pharmacokinetics and preliminary anti-tumour efficacy of
oral SU-014813 administered continuously in combination with docetaxel to patients with
advanced solid tumours.
Methods: In this phase I study successive patient cohorts received docetaxel 60 or 75 mg/m2
every 3 weeks in combination with chronic daily dosing of SU-014813. Dose limiting toxicity
was assessed both in the first and second treatment cycle.
Results: Twenty-five patients were entered on study of which 24 started treatment. Dose
limiting toxicities were prolonged neutropenia, neutropenic fever, fatigue and diarrhoea.
Other toxicities included fatigue, alopecia, nausea, vomiting, anorexia, rash, hypertension
and hair discolouration. The recommended phase II dose was determined to be docetaxel
75 mg/m2 in combination with SU-014813 50 mg/day. There was no clinically relevant phar-
macokinetic drug–drug interaction. Two patients (8%) achieved a partial response (PR) and 7
patients (29%) had stabilisation of their disease (SD) >6 months, for a clinical benefit rate of
37.5%. The activity observed in patients with melanoma and sunitinib refractory gastroin-
testinal stromal tumours (GIST) was particularly noteworthy.
Conclusions: Oral SU-014813 50 mg/day with docetaxel 75 mg/m2 is a clinically feasible reg-
imen with a manageable safety profile and anti-tumour activity. Further development is
warranted in patients with melanoma and GIST.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.al Meeting of the American Society of Clinical Oncology 2008.
ACT 2004-004473-29.
Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA
1338; fax: +31 10 704 1003.
l (M.J.A. de Jonge).
the Elsevier OA license.
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Angiogenesis, the development of new blood vessels from
existing vascular endothelium, plays a vital role in the
growth, invasion andmetastasis of human cancer. In this pro-
cess at least three growth factors are known to be of crucial
importance; the vascular endothelial growth factor (VEGF),
the platelet derived growth factor (PDGF) and the basic fibro-
blast growth factor (bFGF). Over the past decade, inhibition of
VEGF and its receptors have been successfully pursued as
anti-cancer therapy.1–4 The clinical relevance of inhibition of
PDGF and bFGF is yet less well elucidated.
SU-014813 is an oral, indolinone based, multi-targeted
tyrosine kinase inhibitor. In vitro, SU-014813 inhibited VEG-
FR-2, PDGFR-b and FLT3-ITD phosphorylation, with cellular
IC50 values of 0.04, 0.02 and 0.05 lmol/L, respectively, and
showed anti-tumour efficacy in tumour xenograft models.5–8
SU-014813 has oral bioavailability of approximately 40% in
mice. No active metabolite has been demonstrated for
SU-014813 in pre-clinical studies. Sunitinib and SU-014813
receptor targets are similar, SU-014813 was developed as a
follow-up compound to improve pharmacokinetics and safety
characteristics.
SU-014813 was assessed as a single agent in a phase I trial
studying dose ranges of 25–250 mg administered orally and
daily for 4 weeks in 5 weeks cycles (4 + 1 schedule) and in a
continuous daily schedule.9 The recommended single agent
dose for phase II studies is 100 mg administered continuously
daily. Observed side-effectsweremostlymild tomoderate and
included leucocytopenia, thrombocytopenia, hypertension,
fatigue, diarrhoea, skin rash, hair discolouration and asymp-
tomatic increase of plasma lipase levels. Pharmacokinetics in-
creased in a dose-proportional manner and SU14813 was
eliminated with a mean terminal half-life of 9–34 h. In pre-
clinical models enhanced anti-tumour activity was observed
when SU-014813 was combinedwith the cytotoxic agent doce-
taxel. Additionally, recently published data suggest a role for
both VEGFR and PDGFR inhibition in improving the penetra-
tion of cytotoxic agents into tumours.10–13 In tumours, the
interstitial fluid pressure is frequently enhanced as compared
to normal tissue. This pressure potentially acts as a barrier for
tumour transvascular drug transport. Particularly PDGF beta is
a mediator of tumour hypertension through this mechanism.
The ratio of vascular volume to total tumour volume increased
significantly (P < .001) following the administration of a
PDGFR-b inhibitor, suggestive of recruitment of previously
non-functioning vessels.10 VEGF has been suggested to affect
vascular permeability via various mechanisms. This com-
bined effect could partly explain the improved delivery of
cytotoxic drugs to the tumour in animal models.11–13 Since
SU-014813 is a potent inhibitor of both VEGFR and PDGFR, this
was considered as an additional reason to combine the agent
with cytotoxic drugs such as docetaxel.
We performed a dose-finding study of SU-014813 in combi-
nation with docetaxel in patients with solid tumours, with
the primary objective to assess the maximal tolerated dose
(MTD) of oral SU-014813 administered continuously in combi-
nation with docetaxel. Secondary objectives included (a)
evaluation of pharmacokinetics drug interactions betweenSU-014813 and docetaxel and (b) to assess anti-tumour effects
induced by the combination in the patients with measurable
disease.
2. Patients and methods
2.1. Eligibility criteria
Patients with a cytologically or histologically confirmed
diagnosis of an advanced and measurable or evaluable solid
tumour were eligible. Additional criteria included: ageP
18 years; ECOG performance status 0 or 1; an adequate bone
marrow function (haemoglobinP 10 g/dL, platelet countP
100 · 109/L, absolute neutrophil countP 1.5 · 109/L), liver
function (bilirubin 6 1.5 the upper limit of normal (ULN),
alanine aminotransferase and aspartate aminotransfer-
ase 6 2.5 · ULN (5 · ULN in case of liver metastasis in the
presence of a normal alkaline phosphatase), alkaline phos-
phatase 6 2.5 · ULN (5 · ULN in case of bone or liver metasta-
sis in the presence of a normal ALT/AST)) and renal function
(serum creatinine 6 1.5 · ULN) and a serum albuminP
3.0 g/dL.
Specific exclusion criteria included but were not limited to
prior treatment with high-dose chemotherapy requiring stem
cell rescue; prior treatment with docetaxel; prior irradiation to
>25% of the bone marrow reserve; uncontrolled hypertension;
presence of malabsorption due to prior surgery, gastrointesti-
nal disease or an unknown reason or inability to take oral
medication and/or CTCAE grade >2 neuropathy or oedema
from any cause. This study was performed according to the
principles defined by the Declaration of Helsinki in Rotterdam,
The Netherlands and in Leuven, Belgium, and approved by the
institutional ethics committees in both institutions. All the
patients gave written informed consent prior to study entry.
2.2. Study design
SU-014813 (Pfizer Inc.) was supplied as gelatine capsules con-
taining 25 mg or 50 mg of free base equivalent of SU-014813.
The capsules were stored in opaque plastic bottles to protect
the compound from light in a controlled room temperature of
20–25 C. Commercially available docetaxel (Taxotere) was
supplied by the study centres and was stored between 2
and 25 C in its original package to protect it from bright light.
Patients received docetaxel as a 1 h intravenous infusion
every 21 days starting from day 1 in cycle 1. SU-014813 was
administered every morning on an empty stomach with a
glass of water, about 2 h from food intake in cycles of 3 weeks
starting from day 2 in cycle 1. Patients were to receive the
combination SU-014813 and docetaxel for up to 6 cycles in
the absence of any withdrawal criteria that would require
treatment discontinuation. Individual treatment could be
continued at the discretion of the treating physician in the
presence of objective clinical benefit and the absence of
unacceptable toxicity. Initially 3 patients were treated in each
cohort starting with 50 mg SU-014813 and 60 mg/m2 doce-
taxel. All the 3 patients were allowed to be enrolled simulta-
neously. Dose escalation of SU-014813 and docetaxel
proceeded according to predefined dose levels.
Table 1 – Patient baseline characteristics.
Characteristic Number of patients
Age
Mean (year) 54
Range (year) 32–75
Gender
Male 18
Female 6
WHO PS
0 4
1 15
2 5
Tumour type
GIST 4
Melanoma 12
Miscellaneous 8
Prior treatment
Radiotherapy 6
Systemic therapy 22
1–3 regimens 18
>3 regimens 4
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Institute Common Toxicity Criteria (NCI CTCAE) Version 3.0.
The dose limiting toxicity (DLT) was defined in both the
first and second cycle. Since SU-014813 was only adminis-
tered from day 2 of the first cycle onwards, we assumed that
a possible interaction between docetaxel and SU-014813 could
only be fully evaluated during the second cycle since at that
time steady state concentration of SU-014813 was present at
the time of the administration of docetaxel. A DLT was de-
fined as one of the following events: (1) febrile neutropenia,
or grade 4 neutropenia lasting for P7 days, (2) grade P3
thrombocytopenia with bleeding or lastingP7 days; (4) grade
3 or 4 non-haematological toxicities including fatigue lasting
forP7 days (except for skin discolouration, nausea, vomiting
and diarrhoea without optimal supportive therapy and grade
3/4 hyperamylasemia without signs of pancreatitis), (5) grade
P3 hypertension despite optimal treatment (i.e. combination
of 2 anti-hypertensives) and (6) treatment discontinuation for
P2 weeks because of drug related toxicity. Dose modifications
to the next lower dose level were permitted once a patient
had experienced a DLT.
If DLTs were observed in 1 out of 3 patients during the first
or second cycle, up to 3 additional patients were to be treated
at the same dose level. If 1 or none of these additional pa-
tients experienced DLT, the next dose level was to be studied.
If more than one of the additional patients experienced DLT
the maximum tolerated dose (MTD) had been exceeded and
3 more patients were to be treated at the next lower dose le-
vel, if only 3 patients were previously treated at that prior
dose. If DLT had not been observed at the highest dose level
for both docetaxel and SU-014813 then this dose would be
considered the MTD.
If patients withdrew for reasons other than toxicity after
completing only 1 cycle, they were to be replaced. In addition,
patients who experienced significant toxicity attributed only
to docetaxel necessitating dose reduction, were also to be
replaced. Once the MTD was established an additional 9
patients would be enrolled at this dose level.
2.3. Pretreatment and follow-up studies
Before therapy, a complete medical history was taken and a
physical examination was done including ECOG performance
status, body weight, height and vital signs. A complete blood
cell count including WBC differential and serum biochemis-
try, which included total bilirubin, serum transaminases,
alkaline phosphatase, lactic dehydrogenase, amylase, lipase,
albumin, sodium, potassium, chloride, calcium, phosphorus,
blood urea nitrogen, creatinine, uric acid and glucose, were
done as were urinalysis, triplicate 12-lead electrocardiograms
and a pregnancy test (if applicable). The 12 lead electrocardio-
gram was repeated on day 1 of cycle 1 and subsequently if
clinically indicated. Haematology and biochemistry assess-
ments were performed on day 1, 8 and 15 (or more frequently
if clinically indicated) of every cycle. Furthermore, weekly
evaluations on day 1, 8 and 15 of each cycle included physical
examination and toxicity assessments. Pre-medication with
corticosteroids were allowed for 3 days, starting 1 day before
day 1 of every cycle. Tumour imaging was performed within
14 days prior to study treatment, prior to cycles 3 and 5, atregular intervals thereafter, and at termination of study
treatment.
In the protocol a PET assessment using radiolabelled doce-
taxel to measure tumour uptake of radiolabelled docetaxel
was planned at MTD to study the influence of co-administra-
tion of SU-014813 on the tumoural uptake of docetaxel.
Unfortunately no validated method for the radiolabelling of
docetaxel could be developed and this part of the protocol
was not carried out.
2.4. Pharmacokinetic sampling and data analysis
For docetaxel pharmacokinetic (PK) analyses, blood samples
(5 mL) were collected using an indwelling i.v. canula in the
opposite arm of infusion 15 min before dosing (time point 0)
and 0.5, 1, 1.5, 3, 5, 7, 23 and 27 h after start of docetaxel infu-
sion on day 1 of cycle 1 and 2. For SU-014813 PK, blood sam-
ples (2 mL) were collected before dosing and 1, 2, 4, 8 and
24 h after SU-014813 dosing on day 21 of cycle 1 and on day
1 of cycle 2. On day 1 of cycle 2, the day of the second
docetaxel administration, SU-014813 was administered 1 h
before docetaxel infusion. Additionally, trough samples for
SU-014813 were collected prior to dosing on day 1 of all
subsequent cycles. Blood samples for docetaxel as well as
SU-014813 pharmacokinetic analyses were collected into
appropriately labelled tubes containing sodium heparin and
were kept at 4 C until centrifugation within 30 min of collec-
tion at 1500g for 10 min. The plasma samples were divided
into 2 aliquots (2 for docetaxel and 2 for SU-014813) and
stored in appropriately labelled screw-cap polypropylene
tubes at 20 C or below until analysis.
2.5. Data-analysis
All patients who took at least one dose of SU-014813 were
evaluable for all analyses. Descriptive statistics were used to
analyse safety. Pharmacokinetic parameter estimates were
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using non-compartmental analyses (WinNonLin version 4.1).
3. Results
Patient baseline characteristics are presented in Table 1.
Twenty-five patients were entered into the trial 24 of whom
started study treatment. All 24 patients were evaluable for
toxicity and PK analyses. All patients were Caucasian. At
study cut-off, a total of 269 treatment cycles were adminis-
tered, ranging from 2 to 45 cycles across the three dosing
cohorts (2–45 in patients with malignant melanoma and
5–31 in patients with GIST).
In the patients included at the first dose level (SU-014813
50 mg + docetaxel 60 mg/m2) no DLTwas observed. In the sec-
ond dose level (SU-014813 50 mg + docetaxel 75 mg/m2) 1 DLT
(neutropenia G4) was observed in one of the initial 3 patients
treated, therefore 3 additional patients were included. At the
third dose level (SU-014813 100 mg + docetaxel 75 mg/m2) 1
DLT (neutropenic fever) was observed in one of the initial 3
patients. As per protocol, 3 additional patients were included
2 of which experienced a DLT (neutropenic fever and grade 3Table 2 – Overview DLTs.
SU-014813 50 mg + D 75 mg/m2 (N = 15) 1 pt: neutropenia G
1 pt: fatigue G 3
1 pt: febrile neutrop
1 pt: neutropenia G
1 pt: febrile neutrop
SU-014813 100 mg + D 75 mg/m2 (N = 6) 1 pt: febrile neutrop
1 pt: febrile neutrop
1 pt: diarrhoea G 3
D; docetaxel; N; number of patients; pt: patient; G: grade.
Table 3 – Most relevant treatment-related AEs per patient, all cy
Neutropenia Diarrhoea Fatigue An
Grade 1–2 3–4 1–2 3–4 1–2 3–4 1–2
SU-014813 50 mg
+ D 60 mg/m2 (N = 3)
1 1 1 2 0 1 2
SU-014813 50 mg
+ D 75 mg/m2 (N = 15)
0 15 10 2 7 3 10
SU-014813 100 mg
+ D 75 mg/m2 (N = 6)
0 5 2 2 5 1 1
D: docetaxel; N: number of patients.
Table 4 – Relative and absolute dose intensity of docetaxel adm
Dose level Cycles
administere
SU-014813 50 mg + D 60 mg/m2 (N = 3) 27
SU-014813 50 mg + D 75 mg/m2 (N = 15) 111
SU-014813 100 mg + D 75 mg/m2 (N = 6) 33
D: docetaxel; N: number of patients.diarrhoea). Since the MTD was exceeded 9 additional patients
were then enrolled to a total of 15 patients at SU-014813
50 mg/day and docetaxel 75 mg/m2, 5 of whom experienced
a DLT (1 patient with grade 3 fatigue, 1 patient with neutro-
penic fever and grade 4 thrombocytopenia, 2 patients with
prolonged neutropenia and 1 patient with both grade 3 fati-
gue, grade 3 colitis and neutropenic fever) in the first two
treatment cycles. Since 5 out of a total of 15 patients experi-
enced a DLT, which is 1/3 of the patients, this dose level, as
per protocol, was defined as the recommended dose for fur-
ther studies (Table 2).
Table 3 shows the most relevant treatment-related adverse
events. The most common treatment-related grade 3 or 4 AEs
were neutropenia and diarrhoea. While all patients at the rec-
ommended phase II dose level experienced grade 3–4 neutro-
penia, this was complicated by fever in 9 of the 111
administered cycles. Other toxicities included fatigue, alope-
cia, nausea, vomiting and anorexia. Side-effects attributed
to SU-014813 consisted of diarrhoea, rash, hypertension and
hair discolouration. Diarrhoea with abdominal discomfort
was mainly observed in patients continuing on SU-014813
single agent therapy in whom the dose of SU-014813 was4 >7 days Cycle 1
Cycle 2
enia G 4, fatigue G 3, colitis G 3, stomatitis G 3 Cycle 1
4 >7 days Cycle 1
enia and thrombocytopenia G 4 Cycle 1
enia G 4 Cycle 2
enia G 3 Cycle 1
Cycle 2
cles.
orexia Vomiting Rash Hypertension Hair
discolouration
3–4 1–2 3–4 1–2 3–4 1–2 3–4 1–2
0 2 0 1 0 2 0 1
1 7 0 10 0 2 0 1
0 4 0 3 0 0 1 1
inistered per dose level.
d
Relative dose
docetaxel (%)
Actual dose
docetaxel (mg/m2)
95.3 58.2
90.8 66.3
91.9 69.7
Table 5 – Plasma PK parameters of intravenous docetaxel in the presence and absence of SU-014813: geometric mean
[95% CI].
Treatment group Cycle day (N) Cmax (ng/mL) AUCinf (ng * h/mL) T½ (h) CL/F (L/h) Vz/F (L)
1. Docetaxel 60 mg/m2 alonea C1D1 (3) 2202 (1365, 3552) 2326 14.4 47.3 982
1. SU-014813 50 mg/day
+ docetaxel 60 mg/m2a
C2D1 (3) 2266 (1499, 3427) 3305 8.7 33.3 417
2. Docetaxel 75 mg/m2 aloneb C1D1 (13) 2421 (2048, 2860) 3148
(2152, 4606)
14.9
(10.3, 21.4)
43
(31.1, 59.6)
923
(561, 1516)
2. SU-014813 50 mg/day
+ docetaxel 75 mg/m2b
C2D1 (13) 2848 (2340, 3465) 3428
(2252, 5219)
14.9
(11, 20.1)
37.4
(28.3, 49.2)
803
(480, 1344)
3. Docetaxel 75 mg/m2 alonec C1D1 (5) 1977 (584, 6691) 3385
(298, 38514)
15.9
(4, 63.6)
42.2
(3.3, 540)
970
(127, 7434)
3. SU-014813 100 mg/day
+ docetaxel 75 mg/m2c
C2D1 (5) 2150 (1094, 4225) 3616
(895, 14602)
12
(4, 35.4)
36.7
(9.6, 140)
634
(167, 2402)
Abbreviations: AUC24 = area under the plasma concentration–time profile from time zero to 24 h; AUCinf = area under the plasma concentration–
time profile from time zero to infinity; C = cycle; Cmax = maximum plasma concentration; D = day; PK = pharmacokinetic; T½ = terminal half-
life; Tmax = time to Cmax; CL/F = apparent oral clearance; Vz/F = apparent volume of distribution.
a 1D1 and C2D1 – t½, CL, AUCinf and Vz n = 1.
b Data from Subject 10021013 was excluded due to missing PK on C2 D1. C1D1 and C2D1 – t½, CL, AUCinf and Vz n = 7.
c Data from Subject 10021003 was excluded due to missing PK on C1D1. C1D1 and C2D1 – t½, CL, AUCinf and Vz n = 3.
Table 6 – Plasma PK parameters of SU-014813 in the absence and presence of docetaxel: geometric mean [95% CI].
Treatment group Cycle day (N) Cmax (ng/mL) Tmax
a (h) AUC24
(ng * h/mL)
T½ (h) CL/F (L/h) Vz/F (L)
1. SU-014813 50 mg/day aloneb C1D21 (2) 130.3 3 (2–4) 1310 9.7 38.8 535.5
1. SU-014813 50 mg/day
+ docetaxel 60 mg/m2b
C2D1 (2) 108.5 1.5 (1–2) 1237 10.2 40.5 596.1
2. SU-014813 50 mg/day alonec C1D21 (12) 101.3
(76.3, 134.6)
4 (1–8) 1258
(997, 1588)
12.3
(9.8, 15.4)
39.7 (31.5, 50.2) 657
(467, 924)
2. SU-014813 50 mg/day
+ docetaxel 75 mg/m2c
C2D1 (12) 89.6
(70.8, 113.4)
2 (1–24) 1088
(910, 1300)
10.9
(8.7, 13.6)
46.0 (38.5, 54.9) 718
(544, 948)
3. SU-014813 100 mg/day aloned C1D21 (6) 245.3
(170.6, 352.6)
1.5 (0–4) 2820
(1324, 6007)
8.6 35.3 (16.6, 75.5) 332
3. SU-014813 100 mg/day
+ docetaxel 75 mg/m2d
C2D1 (6) 194.7
(112.7, 336.2)
1.5 (0–8) 3168
(1679, 5975)
4.8 31.6 (16.7, 59.5) 286
Abbreviations: AUC24 = area under the plasma concentration–time profile from time zero to 24 h; C = cycle; Cmax = maximum plasma concen-
tration; D = day; PK = pharmacokinetic; T½ = terminal half-life; Tmax = time to Cmax; CL/F = apparent oral clearance; Vz/F = apparent volume of
distribution.
a Median (range).
b Data from Subject 10011001 were excluded due to missing PK on C2 D1.
c Data from Subjects 10011012 and 10021011 were excluded due to missing PK on C1 D21. Data from Subject 10021013 were excluded due to
missing PK on C2 D1; for Cmax, AUC24, Tmax and CL/F n = 12; t½ and Vz/F n = 7.
d For CL/F and AUC24 n = 3; for t½ and Vz/F n = 1.
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treatment with loperamide. Hypertension was easily man-
ageable with antihypertensive agents.
The relative dose intensity of docetaxel at the recom-
mended dose level was 86.4% over all cycles administered,
resulting in an actual dose of 64.8 mg/m2 docetaxel (Table 4).
At the next lower dose level the achieved dose intensity for
docetaxel was 57.0 mg/m2. These data confirm that
SU-014813 in combination with docetaxel 75 mg/m2 is the
recommended dose level for further studies.
3.1. Pharmacokinetics
A summary of the pharmacokinetic data of docetaxel and
SU-014813 is given in Tables 5 and 6. Co-administration with
SU-014813 did not affect the pharmacokinetics of docetaxel.The mean exposure for docetaxel (Cmax, AUC24 and AUCinf)
as well as secondary parameters (t½, CL/F, and Vz/F) were
similar when administered with and without SU-014813.
Furthermore, in general, co-administration with docetaxel
did not affect the plasma pharmacokinetics of SU-014813.
The mean exposure for SU-014813 (Cmax and AUC24) was sim-
ilar when administered with and without docetaxel at both
the 50 mg and the 100 mg dose levels, however, low to moder-
ate variability was observed for the SU-014813 Cmax and AUC24
values.
3.2. Anti-tumour activity
Overall, there were 2 patients (8%) achieving a confirmed par-
tial response (PR) and 12 patients (50%) with stable disease
(SD) for a clinical benefit rate (PR and SD >6 months) of
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Fig. 1 – Waterfall plot percentage change in sum longest diameter tumour compared to baseline.
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lasted more than 6 months (Fig. 1).
Interestingly, 6 out of 12 patients with melanoma showed
clinical benefit. Two patients showed a partial response last-
ing for 36 and 114 weeks. Both patients received prior sys-
temic therapy containing CDDP and DTIC with progression
disease as best response. Both patient had liver metastases
and one patient in addition pulmonary and lymphnode
metastases. The remaining 4 patients showed disease
stabilisation lasting for 12–135 weeks. In addition in 4 patients
with GIST a disease stabilisation could be observed lasting for
15–93 weeks. All of them were imatinib refractory and 3 of
also refractory to sunitinib.
4. Discussion
We performed a phase I dose-finding study on the combina-
tion of a multi-tyrosine kinase inhibitor SU-014813 and doce-
taxel, based on observed pre-clinical data showing additivity
and the hypothesised increase of docetaxel uptake in tumour
tissue due to the decrease in intratumoural interstitial fluid
pressure induced by inhibition of VEGFR and/or PDGFR. Dose
limiting side-effects at the recommended dose level of doce-
taxel 75 mg/m2 and SU-014813 50 mg consisted of neutrope-
nia, neutropenic fever, fatigue and diarrhoea. One of the
intentions of this study was also to establish the compound
as a better partner for combinations with taxanes compared
to other similar multitargeted TKIs.
Neutropenic fever is a well known side-effect of docetaxel
treatment. When administered at doses of 75–100 mg/m2 sin-
gle agent docetaxel induces grade 4 neutropenia in 78.6–88.5%
of patients, complicated by fever in up to 14% of patients.14–16
Furthermore grade 3–4 fatigue is observed in 14.5% of pa-
tients. Against this background toxicity the side-effect fre-
quency in the present combination should be valued. At the
recommended dose 86.7% of patients experienced grade 4neutropenia. Neutropenic fever was observed in 8.1% of all
administered cycles at the recommended dose (9 out of 111
cycles). While a control arm in the current study was obvi-
ously lacking, historical data on docetaxel suggest that the
incidence of both toxicities are in a similar range as those ob-
served on single agent docetaxel.
As a single agent SU-014813 was studied in a 4 weeks on-
1 week off schedule and in a continuous dosing schedule.
The recommended dose for the 4 weeks on-1 week off sche-
dule is 200 mg/day with fatigue as the main DLT. For the
chronic dosing schedule the recommended dose was deter-
mined as 100 mg/day with diarrhoea as DLT.9 Aside from fati-
gue and diarrhoea treatment-related adverse events
constituted of skin rash, hypertension, mild myelosuppres-
sion and hair discolouration.9 These side-effects are in line
with the toxicity observed in the present study.
The observed safety profile for the combination of
SU-014813 and docetaxel is comparable to the side-effects of
the combination of sunitinib and docetaxel.17,18 Also for this
combination neutropenia, fatigue and diarrhoea constituted
the main side-effects. In contrast to the present study the
sunitinib–docetaxel combination appeared to be associated
with more than the expected myelosuppression as compared
to single agent docetaxel treatment and required the intro-
duction of growth factor support in order to tolerate a dose
of 60 mg/m2 docetaxel in combination with sunitinib
37.5 mg/day for two weeks on one week off at least in one
study.17 In combination with prednisone docetaxel 75 mg/
m2 and sunitinib 37.5 mg/day day 1–14 was administered in
patients with hormone refractory prostate cancer without
growth factor support. However, 65% of the patients required
either a dose reduction of sunitinib or docetaxel due to expe-
rienced toxicity.18
Despite the observed toxicity, the tolerance of the combi-
nation SU-014813 and docetaxel seemed acceptable. At the
recommended dose level the median number of days on
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pleted 6 or more combination cycles. Also in the study com-
bining docetaxel and sunitinib 12 out of 40 patients at the
recommended dose level were able to receive the planned 6
cycles.17 Probably this is both indicative of the activity of both
combinations and the absence of cumulative toxicity.
A clinically relevant PK interaction between SU-014813 and
docetaxel was not observed at the recommended dose, simi-
lar to the observations with sunitinib and docetaxel.17
While one should always caution against over-interpreta-
tion of anti-tumour activity in the highly selected phase I
study population, we consider some of our observations in
the present study interesting. Six out of 12 patients with mel-
anoma showed clinical benefit consisting of PR in 2 and pro-
longed SD in 4 patients. Previously reported anti-tumour
activity of docetaxel in melanoma ranged from 14% to
17%.19,20 A randomised phase II study on the combination of
SU-014813 and docetaxel seems therefore warranted.
Furthermore 4 patients with GISTachieved durable disease
stabilisation despite being refractory to previous imatinib
(4pts) and sunitinib (3pts). Docetaxel was never tested in this
patient population, but in general cytotoxic treatment is con-
sidered poorly active in GIST. The profile of SU-014813 is not
sufficiently different from sunitinib to explain the mentioned
responses in sunitinib refractory patients. One might
therefore hypothesise that in line with pre-clinical data,
SU-014813 induced a higher tumoural delivery of docetaxel
due the decrease in intratumoural interstitial fluid pressure
induced by the inhibition of VEGFR and/or PDGFR. This
remains to be elucidated and should be addressed during
further development of this combination. In addition, the re-
sponse rate observed in the phase II study in prostate cancer
combining docetaxel, prednisolone and sunitinib showed a
promising response rate of 39% compared to 12% response
rates in historical data.18,21 In the first randomised study in
breast cancer patients also an increase in response rate was
observed in the combined treatment arm (51% versus 39%).
However, this increase in response rate did not translate in
an increase in progression free survival nor in overall
survival.22
In conclusion a tolerable dose of the combination of
SU14813 and docetaxel could be identified, that yielded inter-
esting anti-tumour activity in a subset of patients. This com-
bination warrants exploration in subsequent randomised
phase II studies.Conflict of interest statement
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